

Cover Story
News Analysis
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Unlocking the future of precision medicine:
The untapped power of RNA - Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime - A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- An opportunity for Trump: Position U.S. cancer science to lead the world
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science